+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight

  • ID: 2720927
  • Report
  • 203 Pages
  • FirstWord Publishing
1 of 2
The December 2013 approval of Gilead's once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the pipeline-led by Gilead, AbbVie, Bristol-Myers Squibb and Boehringer Ingelheim-the battle to transform this potentially lucrative market will be intense.

Therapy Trends: Hepatitis C is compiled from exclusive, in-depth interviews with the world's leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future HCV management.

The authors selected KOLs for this report based on their level of engagement and influence within the HCV pharmaceutical industry, and on their scientific standing. Their unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.

Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained from the field's key opinion leaders. The results of the authors research and analysis will help you to:

- Comprehend the current trends driving and shaping the global HCV market

- Understand the future landscape and how new classes will fit into the treatment algorithm

- Assess the commercial and clinical potential of the pipeline nucs, non-nucs, NS5A inhibitors and next generation protease inhibitors

- Develop planning strategies based on KOL insight

- Identify the unmet needs and opportunities for disease management

- Evaluate the performance of companies with the most robust new product pipelines

- Recognise the key factors KOLs predict will drive future treatment trends

Understand the Global Hepatitis C Market

The hepatitis C (HCV) market is expected to become one of the fastest growing markets in Pharma over the next decade given a sizable 170 million patient population, a significant unmet need and rapid advancements in the clinic. The management of this infectious disease is on the edge of a revolution that will bring considerable changes to the treatment algorithm. KOLs from North America and Europe provide answers to some critical questions regarding the global HCV market, including:

- What do KOLs make of the Sovaldi and Olysio and their impact on treatment?

- What are the current unmet needs and major challenges in HCV treatment?

- What are the most promising late-stage classes in development?

- Which therapies are KOLs eagerly awaiting?

- How will the nucleotide inhibitors, non-nucs, and NS5A inhibitors be positioned in the HCV market?

- How do the second generation protease inhibitors differ from their first-generation cousins?

- In what ways could eventual biomarkers improve future HCV disease management?

- How will treatment of HCV look in the future?

- How do KOLs think the pricing environment will shape the uptake of new HCV treatments?

- What clinical research trends do KOLs predict for future HCV therapies?

Hepatitis C's Panel of Key Opinion Leaders

The authors selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the HCV pharmaceutical industry, and their scientific standing. The HCV KOL panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:

- Adult Viral Hepatitis Prevention Coordinator, Bureau of Epidemiology, Pennsylvania Department of Health, Harrisburg, PA, USA

- Director of Hepatology, Medicine Service, Massachusetts General Hospital, MA, USA

- President and Medical Director at Alamo Medical Research, Texas, USA

- Head, Division of Gastroenterology and Hepatology, Scripps Clinic, CA, USA

- Chief Medical Officer at Alamo Medical Research Texas, USA

- Head of the Liver Institute of Virginia, Virginia, USA

- Department of Hépato-Gastroenterologie, Centre Hospitalier Universitaire de Nancy-Brabois, Vandoeuvre-lès-Nancy, France

- Professor of Medicine at the University of Vienna, Vienna General Hospital, Wien, Austria

- Professor at Hôpital Saint Eloi, Montpellier, France

- Co-lead of HCV Research UK, MRC Virology Unit, Glasgow, Scotland

- Professor of Medicine and Chief of the Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany

Qualitative Analysis Updated Within Days of Major Market Events

Stay a step ahead with Therapy Trends event-driven updates. Over the next 12 months, you will receive updated qualitative analysis each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event's occurrence.

Whether it's a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

An approach backed by unrivalled knowledge

This report provides a qualitative overview of the current and future Hepatitis C (HCV) market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major HCV markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also dictate the dynamics of Pharma markets in other countries.

In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.

Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for HCV, the future of HCV drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing HCV drug classes, the cost of newer drugs and other concerns in the therapy area.
Note: Product cover images may vary from those shown
2 of 2
Current Hepatitis C marketplace

Hepatitis C overview
Current treatment landscape
Reimbursement of key Hepatitis C brands
Unmet needs in Hepatitis C

Current therapies

Pivotal trial data of approved therapies
NS5B nucleoside (Nuc) inhibitors overview
Sovaldi (sofosbuvir; Gilead Sciences) trends
NS3/NS4A Protease inhibitor overview
Olysio (simeprevir; Medivir/Janssen) trends
Incivek/Incivo (telaprevir; Vertex's/ Janssen/Mitsubishi Tanabe) trends
Victrelis (boceprevir; Merck) trends
Interferon and Ribavirin Overview
Pegylated interferon-alpha (Peg-Intron, PegaSys) and ribavirin trends
Current treatment algorithm

Future Hepatitis C marketplace

Future treatment landscape
NS5B nucleoside (Nuc) inhibitors overview
Mericitabine (RO5024048; Roche/Gilead) trends
BMS-986094 (formally INX-189; Bristol Myers Squib) trends
NS5B non-nucleoside inhibitor overview
BI-201127 (Boehringer Ingelheim) trends
ABT-333 (AbbVie) trends
ABT-072 (AbbVie) trends
VX-222 (Vertex) trends
Tegobuvir (GS-9190; Gilead) trends
NS5A replication complex inhibitor overview
Daclatasvir (BMS-790052; Bristol-Myers Squibb) trends
GS-5885 (Gilead Sciences) trends
ABT-267 (AbbVie) trends
ACH-3102 (Achillion) trends
NS3/NS4A protease inhibitor overview
Faldaprevir (BI-201335; Boehringer Ingelheim) trends
ABT-450 (AbbVie/Enanta) trends
Asunaprevir (BMS-650032; Bristol-Myers Squibb) trends
Danoprevir (RO5190591; Roche) trends
Sovaprevir (ACH-1625; Achillion Pharmaceuticals) trends
Vaniprevir (MK-7009; Merck) trends
MK-5172 (Merck) trends
Future treatment algorithm

Future developments in Hepatitis C

Education to raise awareness and improve diagnosis
Clinical trials will evolve in the future
All oral regimen will be approved by 2014
Constrained pricing environments will reduce market access
Effective shorter treatment regimes will emerge
Eventual development of biomarkers will aid treatment
Note: Product cover images may vary from those shown
3 of 2